GLOBAL BLOOD THERAPEUTICS Stock News

The European Commission (EC) has approved Global Blood Therapeutics Inc's (NASDAQ: GBT) Oxbryta (voxelotor) for hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- Sickle Cell Disease Treatment Market Facts at a Glance- Total Pages: 120 Companies: 10+ – Including Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA , Novartis AG, and Pfizer Inc. among others. Coverage: Key drivers, trends, and challenges; Product insights & news; Value chain analysis; Parent market analysis; Vendor landscape; COVID impact & recovery analysis Segments: Indication (sickle cell anemia and others) Geographies: APAC ( China and India ), Europe ( Germany and UK), North America (US), South America , and MEA Didn''t Find What You Were Looking For? Customize Report- Don''t miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

Benzingas weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the duel is between a pair of Black-owned companies in the biopharmaceutical sector : Axsome Therapeutics Inc. (NASDAQ: AXSM ) and Global Blood Therapeutics Inc. (NASDAQ: GBT ). The Case For Axsome Therapeutics: This New York City-based company was founded in 2012 by the Haitian-born Dr. Herriot Tabuteau , who has served as its chairman and CEO since the company began. Tabuteau has a Bachelor of Arts in molecular biology and biochemistry from Wesleyan University and an M.D. from Yale University School of Medicine. He previously worked as an analyst for Goldman Sachs (NYSE: GS ), where he specialized in healthcare analysis, and for HealthCor , a fund focused on healthcare and life sciences. Dr. Herriot Tabuteau Axsome Therapeutics, which has been publicly-traded since 2015, focuses on treating disorders impacting the central nervous system including depression, chronic pain, narcolepsy, fibromyalgia and Alzheimer''s disease.

Benzinga's weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the du

Global Blood Therapeutics <> has recorded its second straight session of losses after Cantor Fitzgerald lowered its price target for the stock citing Omicron-driven disruption to

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Confer

Amid the 2021 Biotech Bear market, GBT shares are still trading at a deep bargain to their true worth. Accumulating shares during a market downturn and patiently holding into the next market upcycle u

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Equities research analysts at SVB Leerink boosted their FY2021 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued on Monday, December 20th. SVB Leerink analyst A. Berens now anticipates that the company will earn ($4.73) per share for the year, up from their []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) SVB Leerink upped their FY2021 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued to investors on Monday, December 20th. SVB Leerink analyst A. Berens now expects that the company will earn ($4.73) per share for the year, up from their prior estimate []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Wedbush lifted their FY2022 earnings estimates for Global Blood Therapeutics in a research note issued on Monday, December 20th. Wedbush analyst L. Moussatos now expects that the company will earn ($4.05) per share for the year, up from their previous forecast of ($4.07). Wedbush has a Buy rating on []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Investment analysts at Oppenheimer cut their Q1 2022 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued on Monday, December 20th. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings of ($1.07) per share for the quarter, down from their [] The post Q1 2022 Earnings Forecast for Global Blood Therapeutics, Inc. (NASDAQ:GBT) Issued By Oppenheimer appeared first on ETF Daily News .

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analysts at Oppenheimer dropped their Q1 2022 earnings estimates for Global Blood Therapeutics in a report issued on Monday, December 20th. Oppenheimer analyst M. Breidenbach now expects that the company will post earnings of ($1.07) per share for the quarter, down from their previous forecast of ($1.03). Oppenheimer also []

Global Blood Therapeutics (NASDAQ:GBT) had its target price decreased by SVB Leerink from $56.00 to $53.00 in a research note released on Tuesday morning, Analyst Price Targets reports. SVB Leerink currently has an outperform rating on the stock. Several other research firms have also recently weighed in on GBT. Royal Bank of Canada decreased their []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) has been assigned an average recommendation of Buy from the fourteen brokerages that are currently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12 month price objective among brokers []